Close

Antimalarials in mosquitoes overcome Anopheles and Plasmodium resistance to malaria control strategies

Douglas G. , Alexandra S. , Erica, Kelsey L., W. Robert, Naresh , Selina , Sarah K., Domombele F.S., Prislaure S.L., Rakiswendé S. , Abdoullaye, Roch K., Thierry, Dyann F., Flaminia

Preprint posted on 25 February 2022 https://www.biorxiv.org/content/10.1101/2021.03.12.435188v2.full

Article now published in PLOS Pathogens at https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1010609

Fighting against the resistance to malaria control strategies by using antimalarials in mosquitoes

Selected by Nassif Seni, Helen Robertson

Background:

Malaria, considered the deathliest parasitic disease, is caused by a parasite from the genus Plasmodium. Malaria results in more than 600,000 deaths annualy. With more than 90% of these deaths, Africa is the most affected continent. Use of insecticides and mosquito nets has helped reduce the number of cases and the number of deaths globally, but with the ongoing development of resistances to insecticides (by the Anopheles mosquito) and to antimalarial drugs by the parasite, it is an emergency to find concrete solutions to those problems in order to avoid the complete resistance to these molecules.

The work led by Paton et al. had as a principal objective to demonstrate the efficacity of antimalarials in mosquitoes. To do so, the team launched on-field analysis in Burkina Faso and laboratory analysis in United States using an antimalarial named Atovaquone (ATQ).

Key Findings:

Exposure to ATQ substantially reduces infection with field Plasmodium falciparum isolates in insecticide-resistant Anopheles coluzzi.

Anopheles coluzzii adult mosquitoes were infected using P. falciparum gametocyte positive blood obtained from a malaria infected human donor on the day of infection. These mosquitoes were then exposed to ATQ for 6 minutes at two concentrations (100 µmol- or 1 mmol/m2) or a mock-treated blank control surface. Infection outcomes were assayed at 7 days post infectious blood meal (pIBM) by dissection of the mosquito midgut. Control-exposed females were robustly infected (81.3% of the sample). In contrast, AcVK5 mosquitoes exposed to either dose of ATQ had significantly reduced P. falciparum infection (99% overall reduction at the highest concentration and 96% overall at the lower dose).

ATQ prevents the transmission of an artemisinin-resistant P. falciparum isolate from the Greater Mekong Subregion (GMS).

Next, a Cambodian artemisinin-resistant Plasmodium falciparum patient clone from the Greater Mekong Subregion was used in combination with Anopheles stephensi. With robust infections, the parasite were observed in control and  mock-exposed mosquitoes (median 16 oocysts per midgut, 100% prevalence of infection), while no oocysts were detected in females exposed to 100 μmol/m2Atovaquone for 6 minutes.

ATQ exposure during an ongoing infection reduces transmission of the parasite and blocks the establishment of the infection.

The authors found that ATQ exposure after oocyst formation has a partial cytostatic effect on P. falciparum. In fact, the size of the developing oocysts had a 45% decrease in the mean oocyst cross-sectional area in mosquitoes of the third generation exposed to ATQ after the infection. Further, no sporozoites were identified in the salivary glands of mosquitoes infected by Plasmodium falciparum and exposed to ATQ plus glucose.

Further related to glucose, Paton et al. tried to determine if antiparasitic elements added to sugar can inhibit the parasite development. After being starved for 24 hours, female Anopheles gambia were fed with a sugar solution combined to Atovaquone 24 hours prior to infection. They obtained a 85% reduction on the prevalence of wild infections due to Plasmodium falciparum in female mosquitoes treated with sugar+ATQ.

With all the experiments that have been done, the antimalarial Atovaquone has shown very interesting results by reducing the infection or the transmission of the Plasmodium parasite.

Importance and personal opinion:

This preprint provides a powerful new approach to fight against malaria, which is a major public health problem in Africa in general, and particularly in Cameroon. It describes a new important aspect considering the killing of the parasite in its first host which is the mosquito. By doing so, this can tackle the transmission of the disease from the mosquito to the human.

In an actual context which is particularly characterised by the rising of resistances of the mosquitoes toward insecticides and impregnated nets and parasites against antimalarial therapy, it is important to find remarkable solutions such as the one presented in this preprint. Adding this new tool to the fight against malaria in addition to other existing ones such as the vaccine can really help communities eradicating the disease.

One particular aspect I really like about the preprint is the ecological and biological aspect of the fight. We are leaving chemical and destructive tools using chemicals to adapt the fight to a biological one. With parasiticidal concentrations, the atovaquone molecule is not toxic for mosquitoes, thus keeping them alive and keeping a certain equilibrium in our ecosystems. Also, the use of attractive sugar baits with Atovaquone which gave very good results was for me very interesting considering the fact that sugar baits can be in the coming years a new tool to fight against the parasite.

 Questions to the authors:

1.      Why did you choose Atovaquone instead of Tafenoquine which is the most recent antimalarial with a sporotoncidal activity?

2.      Knowing the rapid development of resistance in the mosquito population, do we have to be afraid of the development of resistance against Atovaquone?

3.      What can happen if we don’t respect the normal dose of the molecule?

4.      With the extreme variety of mosquitoes and their genetic differences, could this slow the development of antimalarial drugs for mosquitoes?

 

Posted on: 19 August 2022 , updated on: 23 August 2022

doi: https://doi.org/10.1242/prelights.32544

Read preprint (No Ratings Yet)

Have your say

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Sign up to customise the site to your preferences and to receive alerts

Register here

Also in the pharmacology and toxicology category:

FENS 2020

A collection of preprints presented during the virtual meeting of the Federation of European Neuroscience Societies (FENS) in 2020

 



List by Ana Dorrego-Rivas

COVID-19 / SARS-CoV-2 preprints

List of important preprints dealing with the ongoing coronavirus outbreak. See http://covidpreprints.com for additional resources and timeline, and https://connect.biorxiv.org/relate/content/181 for full list of bioRxiv and medRxiv preprints on this topic

 



List by Dey Lab, Zhang-He Goh

1

Drug use in special populations

Any drugs that are being used in special populations: Patients with liver and kidney failure, in paediatrics, in geriatrics, and in pregnant or lactating patients. Includes the discovery of factors that could potentially affect drug use in these special populations.

 



List by Zhang-He Goh

Toxicology of toxicants, existing therapeutics, and investigational drugs

Preprints that describe the toxicology of environmental pollutants and existing and upcoming drugs. Includes both toxicokinetics and toxicodynamics, as well as technological improvements that will help in the characterisation of this field.

 



List by Zhang-He Goh

Anticancer agents: Discovery and clinical use

Preprints that describe the discovery of anticancer agents and their clinical use. Includes both small molecules and macromolecules like biologics.

 



List by Zhang-He Goh

Advances in Drug Delivery

Advances in formulation technology or targeted delivery methods that describe or develop the distribution of small molecules or large macromolecules to specific parts of the body.

 



List by Zhang-He Goh
Close